Autopsy report · NCT02267213

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

“Current study design couldn't support futher development on this indication”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 1 year 3 months before it stopped.
• 29 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Taiwan Liposome Company

Sponsor type

Industry

Conditions

Hepatocellular Carcinoma

Interventions

Lipotecan

Participants

29

Sites

12

Countries

China, Taiwan

Trials that died the same way

• Nitric Oxide During CPB to Reduce AKI in Neonates
  “This study could not be started because of some technical issues.” (63% match in meaning)
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
  “Study design was inadequate and would not achieve study endpoints” (62% match in meaning)
• A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
  “Study design was changed” (61% match in meaning)
• Effect of Chuna Manipulation Therapy on Gait in Patients With Lumbar Disc Herniation
  “Study plan was changed, this project would not be in progress” (61% match in meaning)
• Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
  “Study terminated due to lack of feasibility of study design.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.